Sichuan Biokin Pharmaceutical Co., Ltd. Class ASSE: 688506

Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Iza-Bren (an EGFR×HER3 Bispecific Antibody-Drug Conjugate) for the Treatment of Locally Advanced or Metastatic Nasopharyngeal Carcinoma

· Issued by Sichuan Biokin Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Iza-Bren (an EGFR×HER3 Bispecific Antibody-Drug Conjugate) for the Treatment of Locally Advanced or Metastatic Nasopharyngeal Carcinoma

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis